Observational Study of the Edison System for Liver Tumor Treatment
Collects information on patients with liver tumors treated with the Edison histotripsy device.
Key facts
- Who runs it
- HistoSonics, Inc.
- Where
- Allentown, Altamonte Springs, Austin, Baltimore, Boston, Celebration, Centerville, Chicago, Cleveland, Columbus, Detroit, Fort Myers, Fullerton, Gainesville, Los Angeles, Madison, Manhasset, Miami, Mission Viejo, Mobile, New York, Newport Beach, Reno, Richmond, Rochester, San Francisco, Santa Monica, Seattle, Shreveport, Winston-Salem, and Wyoming, United StatesSee the 35 sites
- Trial code
- Registry title
- Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 14 Oct 2024
- Expected to end
- Nov 2039
- Type of study
- Observational
- Treatments tested
- HistoSonics Edison System
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 22 or older whose liver tumors can be treated, partly or fully, with histotripsy using the HistoSonics Edison System.
- Age
- 22 years or older
- Sex
- All sexes can join.
- Disease stage
- Liver tumors that can be partly or completely treated with histotripsy. Primary, secondary and benign liver tumors are listed as conditions.
Main reasons for not taking part
- Pregnant, planning to become pregnant, or nursing during the study
- Enrolled in an interventional HistoSonics-sponsored trial
- Another condition that, in the investigator's opinion, could jeopardize safety or compliance with the protocol
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Subject is ≥22 years of age
- Subject has signed the Ethics Committee (EC), or Institutional Review Board (IRB) approved study Informed Consent Form (ICF) prior to any study related tests/procedures and is willing to comply with study procedures and required follow-up assessments
- Subject's liver tumor(s) can be partially or completely treated with histotripsy
Who cannot take part
- Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol
- Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period
- Subject is enrolled in an interventional HistoSonics-sponsored trial
Where in United States
- LeHigh Valley HospitalAllentown, United StatesContact: Jessie PanickTaking people
- AdventHealth Altamonte SpringsAltamonte Springs, United StatesContact: Michelle BiedenfeldNo longer taking part
- St. David's Medical CenterAustin, United StatesContact: Krishna SainiTaking people
- Johns Hopkins HospitalBaltimore, United StatesContact: Mehreen NabiTaking people
- Mass General BrighamBoston, United StatesContact: Maggie ConnollyTaking people
- AdventHealth CelebrationCelebration, United StatesContact: Andrea ChiribogaTaking people
- Miami Valley Hospital SouthCenterville, United StatesContact: Katie PughTaking people
- Rush University Medical CenterChicago, United StatesContact: Karl VillanuevaTaking people
- University of ChicagoChicago, United StatesContact: Tiana JacksonTaking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Erlind AllkushiTaking people
- The Ohio State UniversityColumbus, United StatesContact: Gage SpearsTaking people
- Henry Ford HealthDetroit, United StatesContact: Niya BobyTaking people
- Lee Health Cancer InstituteFort Myers, United StatesContact: Lee Health Research DepartmentTaking people
- Providence St. JudeFullerton, United StatesContact: Veronica AguilarTaking people
- Northeast Georgia Medical CenterGainesville, United StatesContact: Trena DavisTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Ali SanfordTaking people
- University of WisconsinMadison, United StatesContact: Caitlin NormoyleTaking people
- Northwell HealthManhasset, United StatesContact: Fellanza Cacaj, MDTaking people
- Baptist Health Miami Cardiac & Vascular InstituteMiami, United StatesContact: Michelle BiedenfeldNo longer taking part
- Mission HospitalMission Viejo, United StatesContact: Kinnedy HoustonTaking people
- University of South AlabamaMobile, United StatesContact: Sara WitheringtonTaking people
- Columbia University Irving Medical CenterNew York, United StatesContact: Anna PeshevaTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Henry KuninTaking people
- NYU Langone HealthNew York, United StatesContact: Stanley CobosTaking people
- Weill Cornell MedicineNew York, United StatesContact: Nishtha SinghTaking people
- HOAGNewport Beach, United StatesContact: Vicki TanTaking people
- Renown Regional Medical CenterReno, United StatesContact: Katie BuckleyTaking people
- Henrico Doctors' HospitalRichmond, United StatesContact: Megan EdwardsTaking people
- University of Rochester Medical CenterRochester, United StatesContact: Cristina Jimenez-SotoTaking people
- Sutter Bay HospitalsSan Francisco, United StatesContact: Maya EshelTaking people
- Providence Saint John's Health CenterSanta Monica, United StatesContact: Joey DumadagTaking people
- Swedish Medical CenterSeattle, United StatesContact: Michelle BiedenfeldNo longer taking part
- Willis Knighton HealthShreveport, United StatesContact: Briana BarrowTaking people
- Novant HealthWinston-Salem, United StatesContact: Alison RankinTaking people
- University of Michigan Health - WestWyoming, United StatesContact: Jensen JantzTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.
The group in the trial
- HistoSonics Edison System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Plain-language title
- Observational Study of the Edison System for Liver Tumor TreatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026